National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
About National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care globally.
NCCN 20th Anniversary Video - Improving Cancer Care Together
January 31, 2015 marked the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 26 academic cancer centers devoted to patient care, research, and education.
Featuring past and present leadership, this video describes the groundbreaking accomplishments of NCCN over the past two decades that have improved the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
127 articles with National Comprehensive Cancer Network
The National Comprehensive Cancer Network® announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.
New research in the April 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography use by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors.
NCCN Announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center as 32nd Member Institution
Tthe National Comprehensive Cancer Network® announced Indiana University Melvin and Bren Simon Comprehensive Cancer Center will be joining the not-for-profit alliance of leading cancer centers as the 32nd Member Institution.
NCCN Pharmacy Directors Forum Publishes Recommendations for Safely Dispensing Investigational Medications for Clinical Trials
The National Comprehensive Cancer Network® announced the publication of new expert consensus recommendations to address routine problems that can occur during prescribing, receiving, storing, preparing, and delivering investigational drugs.
Seattle Cancer Care Alliance Clinicians Present New Research at 63rd Annual Meeting of the American Society of Hematology
Seattle Cancer Care Alliance, the only National Comprehensive Cancer Network -designated cancer center in Washington state, announced that more than 20 of the organization’s clinicians will showcase new research at the 63rd Annual Meeting of the American Society of Hematology, taking place December 11-14, 2021, in Atlanta.
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer.
NCCN Announces Funding for Prostate Cancer Research Projects, in Collaboration with Pfizer and Astellas
The National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) today announced three research projects that have been selected for funding to evaluate neratinib in various tumor types.
The National Comprehensive Cancer Network® hosted a virtual NCCN Policy Summit examining the impact of the past year on oncology policy in America.
The National Comprehensive Cancer Network® announced the publication of new guidance on COVID-19 vaccines for people with cancer, intended to clear up confusion for patients and caregivers.
Free resource from the National Comprehensive Cancer Network helps employers select health plans and provide services to improve employee outcomes and minimize disruptions from cancer diagnoses--now available at NCCN.org/employertoolkit.
NCCN Annual Award Honors Dr. Mary Daly for Key Contributions to Guidelines Program; Recognizes Meetings Department Director with Staff Award
Recognition reflects Dr. Daly's pioneering role in the field of genetics and family history in assessing cancer risk, particularly for breast, ovarian, and pancreatic cancers.
National Comprehensive Cancer Network's Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care, such as cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors
Experts from Northern California-based cancer center to join panels responsible for evidence-based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.
Leading cancer and infectious disease experts analyze latest data and FDA approvals to create evidence-based expert consensus recommendations for both treatment and prevention of COVID-19 for people with cancer.
Results of new study from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
NCCN, ACS CAN, and NMQF present new polling data showing patient, caregiver and provider views of bias and suggest policy and practice changes to improve equity in access to high quality cancer care.
New research found that weight loss after diagnosis was associated with worse outcomes for HER2-positive early breast cancer patients
Incoming leader to oversee fundraising to share trustworthy information about cancer for patients and caregivers as well as supporting promising early-career cancer researchers.